Skip to main content

ARL3 Antibody [PerCP]

Novus Biologicals, part of Bio-Techne | Catalog # NBP2-97379PCP

Novus Biologicals, part of Bio-Techne

Key Product Details

Species Reactivity

Human

Applications

Immunohistochemistry-Paraffin

Label

PerCP (Excitation = 490 nm, Emission = 675 nm)

Antibody Source

Polyclonal Rabbit IgG

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Product Specifications

Immunogen

Produced in rabbits immunized with E. coli-derived Human ARL3 fragment.

Clonality

Polyclonal

Host

Rabbit

Isotype

IgG

Applications for ARL3 Antibody [PerCP]

Application
Recommended Usage

Immunohistochemistry-Paraffin

Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Antigen and protein A Affinity-purified

Formulation

PBS

Preservative

0.05% Sodium Azide

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C in the dark.

Background: ARL3

ADP-ribosylation factor-like 3 is a member of the ADP-ribosylation factor family of GTP-binding proteins. ARL3 binds guanine nucleotides but lacks ADP-ribosylation factor activity. [provided by RefSeq]

Alternate Names

ADP-ribosylation factor-like 3, ARFL3ADP-ribosylation factor-like protein 3, ARF-like 3

Gene Symbol

ARL3

Additional ARL3 Products

Product Documents for ARL3 Antibody [PerCP]

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for ARL3 Antibody [PerCP]

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...